[Special Stock] Inventage Lab Hits Record High on News of Extended Duration for Oral Obesity Drug

Inventage Lab hit a new 52-week high. Investor sentiment was boosted by news that the company had demonstrated, using its proprietary platform technology, the ability to extend the drug maintenance period of an oral obesity treatment to as long as seven days.

As of 9:04 a.m. on April 24, Inventage Lab was trading at 26,300 won, up 26.44% (5,500 won) from the previous day, marking a new 52-week high.

The previous day, media reports stated that Inventage Lab, a developer of long-acting injectable drugs, had proven through its new platform technology that its "oral obesity drug" could maintain its effect for a week and had a superior drug absorption rate compared to global big pharma companies. This news drove the stock price higher. Oral obesity treatments are considered easier to take and store than injectable treatments, and are also seen as having a price advantage, making them more favorable for widespread adoption.

Kim Junghyun, a researcher at Kyobo Securities, said, "Both early and late entrants are considering strategies to differentiate the formulations of their follow-up pipelines. In particular, market participants are paying close attention to the possibility of launching oral or long-acting formulation treatments." Inventage Lab plans to present the research results of this platform technology at the American Diabetes Association (ADA) conference this year.

This content was produced with the assistance of AI translation services.